Form 4: ImmuCell Corp Director Acquires 10,000 Stock Options
SEC Form 4
Director Paul R Wainman acquired 10,000 non-qualified stock options in ImmuCell Corp on September 20, 2024.
Summary
- On September 20, 2024, Paul R Wainman, a director of ImmuCell Corp, acquired 10,000 non-qualified stock options.
- The exercise price of these options is $3.60.
- The options become exercisable on September 20, 2027, and expire on September 20, 2029.
- Following the transaction, Wainman beneficially owns 10,000 derivative securities.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a standard disclosure of stock option grants to a director, which is a common practice.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 09/20/2024 | Date of earliest transaction: Director acquired 10,000 non-qualified stock options. |
| 09/20/2024 | Transaction Date: Director acquired 10,000 non-qualified stock options. |
| 09/20/2027 | Date Exercisable: Options become exercisable. |
| 09/20/2029 | Expiration Date: Options expire. |
| 09/24/2024 | Date of signature by Attorney-in-Fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.